Patents by Inventor Vanessa MORAIS EPIFÂNIO

Vanessa MORAIS EPIFÂNIO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Means and methods for treatment of early-onset Parkinson's disease
    Patent number: 11202795
    Abstract: This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&E
    Inventors: Patrik Verstreken, Vanessa Morais Epifânio, Melissa Vos
  • Restoring phosphorylation of a novel PINK1 substrate to treat parkinson's disease
    Patent number: 9879233
    Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: January 30, 2018
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Bart De Strooper, Patrik Verstreken, Vanessa Morais Epifânio
  • MEANS AND METHODS FOR TREATMENT OF EARLY-ONSET PARKINSON'S DISEASE
    Publication number: 20170319610
    Abstract: This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.
    Type: Application
    Filed: November 20, 2015
    Publication date: November 9, 2017
    Inventors: Patrik Verstreken, Vanessa Morais Epifânio, Melissa Vos
  • RESTORING PHOSPHORYLATION OF A NOVEL PINK1 SUBSTRATE TO TREAT PARKINSON'S DISEASE
    Publication number: 20150299672
    Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 22, 2015
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, VIB VZW
    Inventors: Bart DE STROOPER, Patrik VERSTREKEN, Vanessa MORAIS EPIFÂNIO